Belite Bio, Inc (NASDAQ: BLTE) is a Healthcare company (Biotechnology) with a market capitalization of $6.4B. The Maz Rating grades it against the other companies in its sector.
Belite Bio, Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $157.72, Belite Bio, Inc trades at 8.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -17.0%, return on invested capital of -17.1% and a free cash flow yield of -0.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 33.56. Over the past 52 weeks the share price ranged from $105.88 to $200.00, with a beta of -1.19.
Belite Bio, Inc does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.